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ABSTRACT 
Background: Narrow-band ultraviolet B (NB-UVB) phototherapy is a widely used treatment. 
Psoralen-UVA photochemotherapy (PUVA) increases skin cancer risk and some animal 
studies have raised the possibility of an increased risk with NB-UVB. The risk of skin cancer 
in humans following treatment with NB-UVB is unknown. Objectives: This current analysis 
forms part of an ongoing study ultimately aiming to define the long-term carcinogenic risk of 
NB-UVB treatment in humans. Methods: Details of all patients receiving NB-UVB treatment 
until 31/12/2002 in Tayside, Scotland, were accessed from a treatment database and linked to 
the Scottish Cancer Registry. Indirect standardization was used to compare skin cancer 
incidence in the study population with age and sex matched cancer registry data for the 
Tayside population. We also assessed the effect of NB-UVB exposure treatment numbers on 
the risk of developing skin cancer. Results: Of 4690 records reviewed, 4665 were suitable for 
analysis with 3886 records linked with the cancer registry and 3867 followed-up for at least 6 
months before 31/12/02 (the date at which cancer registration was deemed to be complete). 
The median number of NB-UVB treatments was 29 with 352 patients receiving ≥ 100 
treatments. The study gave 24 753 person-years of follow up. First skin cancers recorded in 
study patients were 27 basal cell carcinomas (BCC), seven squamous cell carcinomas (SCC) 
and six melanomas. No association was found between NB-UVB exposure alone (without 
PUVA) and any skin cancer. For NB-UVB and PUVA treated patients there was an 
association with BCC, with 27 BCCs found compared with 14.1 expected in the matched 
population. Conclusion: We found no significant association between NB-UVB treatment 
and BCC, SCC or melanoma. There was a small increase in BCCs amongst those also treated 
with PUVA. These reassuring results do not demonstrate the early increase in skin cancers 
that was found associated with PUVA treatment. However, cautious interpretation is required 
as the cohort contained relatively few patients who had a high treatment number and because 
the slow evolution of skin cancers may result in a delayed incidence peak. Ongoing risk 
assessment is therefore essential. 
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